Australia's most trusted
source of pharma news
Friday, 01 May 2026
">
Posted 1 May 2026 AM
Takeda’s “ongoing investment in oncology” has paid off with the PBS listing of anti-VEGF agent Fruzaqla, according to the company’s Oceania General Manager, Dave Pearce.
The Japanese pharma first submitted Fruzaqla to the PBAC’s July 2024 meeting, however as the drug was still awaiting the TGA’s approval, it was pushed into the September intracycle meeting at which it was recommended for PBS listing.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.